Korro Bio, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On August 5, 2026, Korro Bio agreed with three Venrock entities (VENROCK HEALTHCARE CAPITAL PARTNERS EG L.P., VENROCK HEALTHCARE CAPITAL PARTNERS III L.P., and VHCP CO-INVESTMENT HOLDINGS III LLC) to exchange 1,000,000 shares of common stock surrendered for no consideration in exchange for pre-funded warrants to purchase 1,000,000 shares at $0.001 exercise price. Closing was scheduled for August 6, 2026. The warrants are perpetual, exercisable via cashless exercise, and include a 9.99% ownership cap (adjustable to 19.99% with 61-day notice). No other dollar amounts, pricing, or financial consideration disclosed beyond the 1M share equivalence.
Why this rating
Share exchange—no cash/debt involved. 1M shares ≈1.1% of ~89M market cap; modest dilution offset by Venrock's continued upside participation via warrants. Routine capital structure adjustment.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.